U.S., Nov. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07909304) titled 'Romosozumab and Denosumab Combination Therapy for Osteoporosis' on Oct. 26.

Brief Summary: In this research study we want to learn more about the effect of two different FDA-approved medications in the treatment of osteoporosis.

Study Start Date: Jan., 2027

Study Type: INTERVENTIONAL

Condition: Postmenopausal Osteoporosis

Intervention: DRUG: Romosozumab

Monthly romosozumab

DRUG: Romosozumab and Denosumab

Monthly romosozumab, Every 6 months denosumab

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Massachusetts General Hospital

Information provided by (Responsible Party): Elaine W. Yu, Massachusetts General Hospital

Discl...